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Abstract
Eukaryotic cells contain an extensive amount of GTP/GDP binding proteins. Proteins
known as Ras GTPase primary function as a binary switch, where they cycle from an on and off
state when GTP or GDP are bound, respectively. They are known to play a critical role in many
cellular functions where a dysregulation could potentially lead to oncogenic behavior or other
malignancies. In our laboratory, our focus is the study of a Ras related protein Cell division
control 42 homolog (Cdc42) which belongs to the Rho subfamily. Cdc42 plays a critical role in
many biological signaling processes; therefore, its uncontrol gene expression has been known to
play a pivotal role in cancer cell progression and metastasis. A single point mutation was done
on Cdc42 where a Threonine(T) was replaced to an Alanine(A) at position 35 (Cdc42(T35A)),
this demonstrated a decrease in the flexibility in a region that is important for the interactions of
downstream effector proteins.1 AZA197 has been demonstrated to show selectivity to Cdc42 and
inhibit colon rectal tumor growth.2 The purpose of this research was to successfully synthesize
the small molecule, AZA197, and study its interaction with Cdc42. Fluorescence spectroscopy
was used in both characterizations of Cdc42(WT) and Cdc42(T35A) interactions with AZA197.
The data suggest that in the presence of AZA197 Cdc42(WT) is more resistant to protein
denaturation and has an increase in the Gibbs free energy of unfolding in the absence of GnHCl.
Results also highlighted that AZA197 also interacts with Cdc42(T35A) and may have a
destabilizing effect on this Cdc42 variant.
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Abbreviations
BME

β-mercaptoethanol

CD

Circular dichroism

Cdc42

Cell division cycle 42

Cdc42(T35A)

Cell division cycle 42 in which Threonine at
residue 35 has been mutated to Alanine

CV

Colum Volume

DNAse

Deoxyriboribonuclease I, from bovine
pancreas

EDTA

Ethylenediaminetetraacetic acid

FPLC

Fast Protein Liquid Chromatography

GAP

GTPase Activating Protein

GDI

Guanine dissociation inhibitor

GDP

Guanosine diphosphate

GEF

Guanine Exchange Factors

GMPPNP

β,γ-Methyleneguanosine 5′-triphosphate
sodium salt; a nonhydrolyzable GTP analog

GTP

Guanosine triphosphate

GTPase

GTP hydrolyzing protein

GnHCl

Guanidinum hydrochloride

His6

Hexahistidine tag; affinity tag

IPTG

Isopropyl-β-d-thiogalactopyranoside

ITC

Isothermal titration calorimetry

LB

Lysogeny Broth

NMR

Nuclear magnetic resonance

PAK

p-21 activated kinase

PBD46

46 amino acid derivative of PAK-21 binding
domain

PBS

Phosphate buffered saline

PDB

Protein Data Bank

Pi

Inorganic phosphate

PMSF

Phenylmethanesulfonuylfloride

RBD

Ras binding domain

SDS

Sodium dodecyl sulfate

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel
electrophoresis

TCA

Trichloroacetic acid

WT

Wild type

Chapter I-Introduction
Ras proteins
Ras or Rat Sarcoma genes were first identified and characterized as transduced oncogenes.3
The Ras protein family is composed of small molecular weight GTPase proteins that contribute
to a series of diverse biological roles upon interaction with specific regulatory and effector
proteins. GTPase proteins primarily function as molecular switches, as they cycle between
Guanosine Triphosphate (GTP) and Guanosine Diphosphate (GDP), known as the on and off
states, respectively. The Human Ras superfamily contains 153 protein members, that contribute
to various signal transduction pathways, making them a perfect candidate to study proteinprotein interactions.4, 5 They also have the potential to be utilized as targets for therapeutic
treatments such as cancer or other diseases.
The Ras superfamily are a GTPase protein characterized by a Gbox domain that is found on
the N-terminal side that is responsible for the GTP binding and hydrolysis biochemical activity.3,
4, 6

The “G box” is separated into five different segments, G1-G5, involving the GTP/GDP

binding region, and an active site for the common mechanism of GTPase proteins. The G1 box is
known as the P-loop, a purine nucleotide binding region.3, 6The G2 box has a Threonine residue
at position 35, that is highly conserved among the Ras superfamily.3 The G3 box sequence has an
aspartic acid residue, responsible for participating in the binding of a nucleotide-associated Mg2+
ion.3, 6 The G4 box plays a role in the hydrogen bonding of the guanine ring, providing the
stabilizing interactions within the G1 box.3 The G5 box is the least conserved among the
superfamily and it’s believed to be involved in indirect associations with the guanine nucleotide.3
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Rho Proteins
Rho proteins are a subfamily within Ras proteins that contain a highly conserved region
within the G box.7 Nonetheless, some members of this group are uniquely differentiated by
containing a specific sequence among all Ras superfamily proteins.3, 8 They are low molecular
weight proteins that are mainly found in the cytoplasm.3, 8 Rho proteins are divided into six
different families based on sequence similarities and are further characterized into typical and
atypical GTPases depending upon its mode of regulation.5
The Rho GTPases family contributes to cellular processes such as: organization of actin and
microtubules in the cytoskeleton, regulation of gene expression, vesicle trafficking, cell cycle
progression, cell morphogenesis, cell polarity, and cell migration.5, 9, 10 In addition, Rho proteins
are involved in inflammation process, wound repairs, and cancer progression.9
Specifically, the human Rho family is composed of 23 proteins that are divided into 8
categories depending on their type of regulation, typical or atypical.11 Typical regulation refers to
the GTPase proteins dependency on Guanine nucleotide exchange factors (GEFs) and GTPase
activating proteins (GAPs).9 Atypical regulation of GTPase protein do not depend on regulatory
proteins but are believed to use post-translational modifications for its regulation and
expression.9
Typical regulation of Rho proteins rely on three main effector proteins: GAPs, GEFs, and
Guanine nucleotide dissociation inhibitors (GDIs).5, 8, 9 As mentioned above, GTPase proteins
cycle between an active and inactive state, GTP and GDP, respectively. GEFs are proteins that
facilitate the exchange of GDP (inactive) to GTP (active). GAPs are responsible for facilitating
the hydrolysis of GTP (active to inactive) by providing an essential catalytic group.8, 9, 12 The
other regulator protein, GDIs, are responsible for the activation regulation and control the
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location of some Rho GTPases within the cell, either in the cytoplasm or on the plasma
membrane.8, 9, 12 Once a GTPase protein is bound to GTP they have a greater affinity for binding
to downstream effector proteins.
Rho GTPases play a significant role in the regulation of cell migration, proliferation, cell
survival, and apoptosis.9 All of this is necessary for the maintenance of normal tissues, but a
slight dysregulation could lead to the progression of cancer. The process of oncogenesis, the
initiation of cancer cells from normal cells, is a multi-step process from environmental and
genetic factors. This results in an imbalance of certain cellular processes such as, cell
proliferation or the inhibition of apoptosis leading to the uncontrolled replication of cells i.e.,
immortalization. Cell division control 42 (Cdc42), Ras homolog gene family A (RhoA), and Ras
related C3 botulinum substrate 1(Rac1) are among some of the Rho subfamily proteins that have
been identified to play a role in the progression and metastasis of different human tumors.9
Cdc42 (WT and T35A)
Cdc42 is a member of the typical Rho GTPase family known to play a significant role in
cancer progression and is tissue specific. For example, in non-small lung cancer, colorectal,
adenocarcinoma, melanoma, lung, and breast cancer it has been upregulated, and for kidney,
central nervous system, and adrenal gland cancers it is downregulated.
Cdc42 is a small GTPase protein that has a molecular weight of approximately 21kDa
and its secondary sequence is composed of 6 β sheets and 5 α helices.13, 14
This protein contains 11 homologs ranging in molecular size from 190 to 193 amino
acids.10 It contains a particular domain unique among other Ras proteins, known as the Rhoinsert domain (RI) composed of 13 amino acids which serve as a recognition region for
downstream effectors.14
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In humans, there are two major isoforms of Cdc42 and they are composed of two main
regions known as the Switch I (residues 28-41) and Switch II (residues 57-74).1, 7 The Switch I
and Switch II regions are highly conserved regions among Cdc42 isoforms.1, 7 These two regions
have demonstrated internal dynamics that allow them to interact with several regulatory and
effector proteins efficiently. Cdc42 can interact with effector/adaptor proteins such as kinases,
phospholipases, and actin associated proteins. Cdc42 undergoes post-translational modification
at the C-terminal side on the Cys residue pivotal for its attachment to the plasma membrane.14
Downstream effector proteins contain a Cdc42/Rac interactive binding domain (CRIB domain)
important for the binding of downstream effector proteins with Cdc42 The specificity of the
effector proteins interaction with Cdc42 is believed to take place with different residues within
the Switch I region.15 This leads to a competition between effector and regulatory proteins, i.e.,
different interactions at the different times in the cell cycle.
A single point mutation on Cdc42 wild type (WT) was performed, replacing a Threonine
with an Alanine at position 35 known as Cdc42(T35A) to study Cdc42 backbone flexibility and
the overall stability of the protein.7 This mutation was done inside the Switch I region that has
been recognized to play a role in interacting with downstream effector proteins, upon Cdc42
being active.1 This single point mutation demonstrated no destruction in the overall tertiary
structure of the protein and had no effect on its activity.7 Cdc42(T35A) is believed to reduce the
overall flexibility of the Switch I region.1 This point mutation is significant because Threonine at
position 35 is highly conserved among all Ras family proteins.1, 7 The point mutation not only
demonstrated a reduce flexibility with in the Switch I region but a weak interaction was observed
from a protein known as PBD46.1, 16 This protein is a partial segment of p21-activated
serine/threonine kinase (PAK1) that interacts with active Cdc42 it was demonstrated to reduce its
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interaction in comparison with the Cdc42(WT).1, 16, 17 In an in vivo study performed in mammals,
Cdc42 has been proven to play a significant role in the regulation of the bones and the
cardiovascular, immune, and nervous systems.18 Cdc42 has the potential to be studied as a model
for structure-function relationship of cell signaling processes such as actin dynamics, migration,
survival, and cell cycle progression.8, 19, 20 Additionally, its important role in the progression of
cancer and other diseases has led current research to focus on small molecules and microRNAs
as new candidates for treatment.21-23
Cdc42 in Cancer
Cancer develops when an accumulation of genetically and epigenetic changes occur on
tumor suppressor genes and oncogenes.10, 11, 24 Targeted therapeutic treatment depends on the
specific molecular mechanism responsible for the progression of the disease. Cancer cells are
unique in their ability to alter the intermediate metabolism. They are able to alter the glycolysis
pathway by the phosphorylation of the PKM2 enzyme that leads to the formation of lactic acid
instead of acetyl CoA creating an acidic environment.10 The acidic environment has also been
related to an increase in tumor progression.10 Cdc42 is usually not mutated in cancer cells but
rather overexpressed or hyperactivated, and in human cancers they are mainly activated due to an
upregulation of GEF’s.11, 12, 25, 26
Cdc42 in its active state has been known to interact with several downstream proteins
such as PAK, PI3K-AKT, and Raf Merk-Erk pathways.27 Therefore, recent efforts have been
made to find inhibitory candidates between specific GEF’s and Cdc42.27 ZCL278 is a small
molecule demonstrated to inhibit the protein intersecting (ITSN), a specific Cdc42 GEF, leading
to a reduction in cell mobility and the disruption of the Golgi organization.28 Another successful
derivative from the ZCL compounds is ZCL367 that resulted in a halt of cancer progression in
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Human A56 lung cancer cells and its high selectivity of Cdc42 in comparison to other Rho
proteins.27
Cdc42 can be used as a molecular marker for the identification of early-stage cancers
such as for the early detection of pancreatic ductal adrenal carcinoma, PDAC.26 Pancreatic
cancer is known to have no preliminary signs and symptoms, and unfortunately this leads to its
diagnosis at a later stage with poor prognosis.26 In a study it was found that there is a direct
relationship between pancreatic carcinogenesis and Cdc42 overexpression.26
Another recent therapeutic discovery was the use of a small non-coding microRNA
(miRNA), known to assist in post-transcriptional regulations that play a role in the physiological
and pathological processes.22, 24, 29 miRNA can serve as therapeutic agents or biomarkers for
certain cancers. One example is the MicroRNA-548J which has been identified to be
overexpressed in breast cancer cell lines, known as invasion-inducing miRNA.22 MicroRNA548J was demonstrated to activate Tensin1 that is related to the activation of Cdc42.22 The
selective inhibitor known as ML141 was demonstrated to suppress microRNA-548J mediated
cell invasion.22 Furthermore, it was demonstrated that microRNA-548J and Tensin1 have a
strong correlation in regards to breast cancer cell invasion and metastasis.22
AZA197
A small organic molecule known as AZA197 was found to suppress tumor growth of
colon rectal cancer (CRC), and has demonstrated a selectivity of Cdc42 over other Rho proteins.2
This highlighted the potential of Cdc42 as a candidate for targeted therapies to treat malignancies
related to its overexpression.2
Cdc42 has been known to play a key role in the progression of cancer even though it is
tissue specific. One downstream signal that Cdc42 tends to interact with is PAK1.2 The
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overexpression of PAK1 has been associated to be an aggressive sign of the CRC disease
progression.2 Additionality, Cdc42 has also been proven to be overexpressed suggesting a
potential role in the tumor development.2 In a study using cell lines, SW620 (highly invasive
colorectal cancer cells) and HT-29 (colorectal cancer cells), it was demonstrated that after being
treated with AZA197 there was a reduction in cell migration and invasion.2 It was demonstrated
in the in vivo portion of the study that SW620 colon cancer xenografts had reduced tumor
growth after being treated with 10 µM AZA197 for twenty days as compared to the control
xenografts that had not been treated with the small molecule.2
The synthesis of AZA197 was based on a chemical compound from the National Cancer
Institute Chemical Database that was used to target against the Rho GTPase protein, Rac A.2
Using a free docking database known as ZINC, 17 small organic molecules were synthesized by
a company called SPECS located in the Netherlands.2 All seventeen molecules were carefully
evaluated and only AZA197 exhibited strong inhibitory activity in SW620 cells.2 The study
demonstrated that based on a cytotoxicity assay the optimum concentration of AZA197 is 10
µM. Another assay performed was to identify if the GTPases; Rho, Rac1, and Cdc42 would
interact with the small molecule in both cell lines.2 This demonstrated that AZA197 specifically
and significantly downregulates Cdc42 activity in a dosage dependent manner, while there was
no significant effect on Rac1 or RhoA.2 Next it was determined whether or not AZA197 hinders
the interaction between Cdc42 and the Dbs protein, a particular Cdc42 GEF protein.2 The
experiment concluded that AZA197 blocks the interaction of Dbs and Cdc42, halting the
activation of Cdc42 resulting in its inhibition.2 An in vivo experiment was also performed
treating mice with SW620 xenografts in the presence and absence of the small molecule for
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twenty days.2 The results reveled that in the mice that were treated with the small molecule the
tumor weight was suppressed and resulted in prolonged animal survival.2
Chapter II-Experimental Methods
Growth, Expression, and Harvest
Cdc42(WT) and Cdc42(T35A) constructs are overexpressed using a (N-His6) tag from
pET15b in Escherichia Coli strain, BL21(DE3), in LB media. In a 500 mL Erlenmeyer flask
containing 100 mL of LB media, 100 uL of ampicillin (AMP), and a 1 mL bacterial glycerol
stock, containing 500 uL of 50% glycerol and 500 uL of the overnight culture, was used to make
an overnight culture growth that was left shaking for 15 hours at a constant speed and
temperature of 37°C. Upon completion, the overnight culture is used to inoculate a 6 L
Erlenmeyer flask containing 1.5 L of LB media and 750 uL of AMP utilizing the same
conditions. For the next couple of hours, the culture was monitored until the optimum optical
density (OD) was reached, 0.4-0.6. A Varian Cary 50 bioUV-vis Spectroscopy was used to
measure the OD of the culture at a wavelength of 600 nm. Once the optimal OD was reached, the
culture was induced with 0.5 mM Isopropyl-beta-D-thioglactopyranoside (IPTG) and was left to
express for four hours in the shaker under the same conditions. After expression, the cells are
harvest by centrifugation at 6,500 rpm for 30 minutes at 4oC. The cell pellet is collected, and the
supernatant is discarded. The cell pellet is resuspended with 1x PBS Buffer solution (pH 7.4) and
centrifuged again at 4,500 rpm for 12 minutes to washout left over LB media. The supernatant is
again discarded, and the cell pellet is stored at –80oC.
Protein Purification
A 5 mL His-Trap FF column was cleaned and regenerated by the following protocol: 5 cv
(1 column volume (cv) = 5 mL) of 20% ethanol, 10 cv of deionized water, 3 cv of 1x stripping
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buffer, 5 cv of deionized water, 3 cv of 1x binding buffer, 2 cv of 1x charging buffer, and 4 cv of
deionized water.
A cell pellet was left to thaw on ice and resuspended in lysis buffer. The lysis buffer
contains: 45 mL of Tris/NaCl binding buffer (40 mM imidazole, 100 mM NaCl, 50 mM Tris (pH
8.0), and 10 mM MgCl2), 45 mg of lysozyme, 90 uL of phenylmethylsulfonyl fluoride (PMSF),
160 uL of Halt protease, and a pinch of Bovine DNAse. The cell pellet on ice undergoes a
sonication cycle, where the sample was sonicated every other ten seconds for five minutes. The
cell debris and soluble components are separated by centrifugation at 19,000 rpm for 35 minutes.
The supernatant is collected and filtered and left on ice to prevent proteins degradation.
The proteins are purified by affinity chromatography using a Fast Protein Liquid
Chromatography (FPLC) machine. Using the ÄKTA Start system (FPLC, GE Healthcare) with a
5 mL His-Trap FF column, lysis buffer, binding buffer, and elution buffer were all added into
their respective place on the FPLC for the protein purification process The column is first
equilibrated with binding buffer, and upon equilibration the lysis buffer will be passed through
the column. The lysis buffer interacts with the column and the protein of interest will bind to the
column while everything else passes through the column. The column is then washed with
binding buffer to remove unwanted proteins. An increasing linear gradient of elution buffer starts
to run through the column until 100% of elution buffer has been reached. Allowing for the bound
protein to come off the column and into the collection tubes. Once this takes place the column is
re-equilibrated. After the cycle is completed, the column is removed, and everything is cleaned
according to manufacture protocol. Figure 2.1 represents an example of a chromatogram from
Cdc42(T35A) after the purification process is complete. The binding phase is illustrated by the
first peak between 40-65 mL. In which the lysis buffer passes through the column, where all
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unwanted proteins will elute and the protein of interested will remain in the column. The
washing phase is between 65-115 mL, where binding buffer is passed through the column to
make sure any unwanted protein is eluted out of the column. The Elution phase is represented
from 115-160 mL, where at first a linear gradient of increasing concentration of elution buffer
will be added to the column to remove the protein of interest. To make sure the protein of
interest is unbound a 100% elution buffer solution will be added to the column. In this case
fractions 9-11 where collected. A Chromatograph of the purification of Cdc42(WT)is shown in
figure 2.2. The binding phase of the purification process was observed between 0-30 mL. The
washing out phase is demonstrated in the 30-80 mL to ensure the unwanted protein was
completely washed out. The elution phase is demonstrated in the 80-120 mL, where Cdc42(WT)
was eluted out, in this case fractions 10-16 where collected.

Figure 2.1. Depicts a chromatogram from the purification of Cdc42(T35A), in this case fractions
9-11 were collected. The y-axis is a measure of the absorbance units (mAU), and the x-axis
10

represents the volume (mL) used. The blue line depicts the absorbance units, and the pink line
represents the gradual increase of elution buffer used in order to unbind the protein of interest
from the column.

Figure 2.2. Affinity chromatography showing the purification of Cdc42(WT). The blue line
depicts the absorbance units (mAU), and the pink line represents the gradual increase of elution
buffer used in order to unbind the protein of interest from the column.
Once the purification process was completed the collection tubes were collected and
placed in ice. A 20 uL sample from each collection tube was collected and placed into a 1.5 mL
microcentrifuge tube with 10 uL of 2X dye to make gel samples to run an SDS-Page. Once the
gel samples were obtained the collection fraction tubes from the purification were combined and
added into a dialysis bag with a molecular cut off weight of 4-6 kDa, which was then placed in
dialysis buffer (100 mM NaCl, 20 mM Tris, and 10 mM MgCl2 (pH of 8.0)) overnight at 4oC.
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Gel Electrophoresis
The presence and condition of the protein was confirmed by SDS-Page gel
electrophoresis. The gel was composed of a 15% bis acrylamide mixture. The 1.5 mL
microcentrifuge tubes collected from the purification were used, and the gel was run according to
protocol. Once completed it was washed with water, stained for 10 minutes, and destained
overnight, then washed with distilled water and scanned. Figure 2.3 reveals a gel obtained from
two different purifications. The first band represents the molecular weight ladder, where is a set
of weights standards to identify approximate weights of proteins. The Lys or Lysis buffer is the
sample obtained before the purification. The flow or flow through represent the washing phase of
the FPLC, where all of the proteins not bound to the column are eluted out (similar to the peak
between 65-115 mL in figure 2.1). The 10-14 columns are the actual sample gels collected form
the elution phase.

Figure 2.3. SDS-PAGE electrophoresis confirming the presence of a Cdc42(WT) based on the
molecular weight. Two purifications were performed independently from each other. The Lys
represents the sample obtained before the purification. The flow is the sample obtained during
the binding phase of the purification, and the numbers correspond to the fractions collected
during the elution phase of the purification, in this particular case fractions 10-14 were collected.
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Nucleotide Exchange
A nucleotide exchange assay was performed to exchange the GTP to a nonhydrolyzable
form of GTP. The protein was transferred from the dialysis bag into a 15 mL Falcon tube, and
the concentration was checked with the Bradford protein assay and later corrected using the
correct molar absorptivity and molecular weight depending on the protein of interest. Once the
concentration of the protein was obtained, it was then incubated with the GTP analog, β,γMethyleneguanosine 5′-triphosphate sodium salt. The GTP analog serves to conserve the protein
in its active state. In addition to the GTP analog, 0.5 mM of EDTA is added and left for an
incubation period of 3.5 hours, at a temperature of 4oC, on a gentle shaker. A desalting column,
PD-10, was equilibrated with 50 mL of 1X PBS buffer (pH 7.4) and the protein was passed
through the column and collected in 1 mL microcentrifuge tubes. Each collection tube was
analyzed using a Bradford Assay to determine its location. Protein Fractions were obtained and
0.1 M MgCl2 is added to the sample and the concentration was checked and stored at -80oC.
Chapter III-Experimental Results
Synthesis of AZA197
The synthesis of AZA197 was done in collaboration with the McIntosh Group. The
synthesis involved a two-step reaction. Figure 3.1 illustrate the first step of the reaction
synthesis, where Tryptamine (2 molar equivalence) and triethylamine (1 molar equivalence) in
acetonitrile were mixed in a round bottom flask. Once in solution dichloro-6-methylpyrimidine
(1 molar equivalence) was added. The reaction ran at 70oC for 16 hours. The reaction was
concentrated and both isomeric products were isolated using a TLC Flash Chromatograph
AKROS machine. Products were eluted using 60:40 hexane: ethyl acetate, the compounds after
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being concentrated were a yellow-brown solid. Table 3.1 demonstrates the optimizations used in
order to obtain the first reaction.

Figure 3.1. Illustrates the first step reaction synthesis.
Table 3.1 Shows the reactions done to optimize the first reaction.
Tryptamine
2-4-Dichloro-6Temperature
Time
Solvent
(equivalence) methylpyrimidine
(equivalence)
1
2
30oC
17hrs
THF
1
2
70oC
17hrs
THF
o
1
2
70 C
15hrs Triethylamine
and
acetonitrile

Successful
No
No
Yes

Figures 3.2-3.5 illustrate the proton NMRs obtained for the reaction. Figure 3.2 is a
proton NMR performed after adding Tryptamine and 2,4-Dichloro-6methylpyrimidine in order
to obtain a preliminary NMR of the reactants. Figure 3.3 is a proton NMR obtained after the
reaction was completed and concentrated before the separation of the two isomers. Figures 3.4
and 3.5 are the proton NMRs after both constitutional isomers where successfully separated and
concentrated. Figure 3.4 illustrates the isomer of interest, a successfully synthesized AZA197, 1H
NMR (CDCl3): 2.3(s,3H), 3.08-3.12(t,2H), 3.668(s,2H), 6.01(s,1H), 7.071(s,1H),7.137.16(m,1H), 7.2-7.22(m,1H),7.43-7.405(d,1H),7.64-7.62(d,1H). Figure 3.5 depicts the unwanted
isomer 1H NMR (CDCl3): 2.3(s,3H), 3.06-3.08(t,2H), 3.7-3.8(t,2H), 6.45(s,1H),
7.071(s,1H),7.13-7.16(m,1H), 7.2-7.22(m,1H),7.37-7.39(d,1H),7.68-7.7(d,1H).
14

15
Figure 3.2. Illustrates a Proton NMR of the two reagents added together. Tryptamine and 2-4-Dichloro-6-methylpyrimidine.

16
Figure3.3. Illustrates the proton NMR after the reaction was completed and concentrated. Both Isomers are still not separated.

17
Figure 3.4. Illustrates the isomer of interest after its separation and concentration. The main difference between the constitutional
isomers are within the peaks on box C and B.
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Figure 3.5. Illustrates the unwanted isomer after its separation and concentration. The main difference between the constitutional
isomers are within the peaks on box C and B.

The Mass spectra was done after successfully isolating both isomers to confirm that both
had the corresponding molecular weight of the compounds, which is 286.76 g/mol, and the
composition of C15H15N4Cl. Figures 3.6 and 3.7 illustrate the mass spectra obtained from the
wanted isomer and the unwanted isomer, respectively.

Figure 3.6. Illustrates the ESI Mass spectrum obtained for the isomer of interest.
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Figure 3.7. Illustrates the ESI Mass Spectrum obtained from the isomer that was not
needed.
For the second step of the reaction synthesis Isomer B and 4-amino-1diethylaminopentane were reacted in a 1:1 molar ratio without any solvent as depicted in Figure
3.8.

Figure 3.8. A visual representation of the second step of the reaction synthesis This was
performed after isomer B has been successfully isolated.
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The reaction was performed using a CEM Discover microwave machine under the
following settings: pressure 15 psi, temperature 120oC, and reacted for one hour and 45 minutes.
The product was a brown solid with a 62% yield. Table 3.2 represents the optimization
conditions for the second reaction before the final reaction conditions was established.
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Table 3.2. Optimization conditions for the second reaction.
Isomer B
4-amino
Temperature
Time
Pressure
(equivalence)
-1(PSI)
diethylaminopent
ane (equivalence)
1
1.1
130oC
17hrs
N/A

Solvent

Successful

Oil bath

No

No
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1

1.2

60oC

18hrs

N/A

Oil bath

Triethylamine
and ethanol

No

1

1.5

70oC

18hrs

N/A

Oil bath

No

No

1

1.5

78oC

20min

30

No

No

1

1.5

78oC

20min

20

No

No

1

1.5

120oC

30min

20

No

No

1

1.5

130oC

30min

25

No

No

1

1.5

130oC

90min

25

No

No

1

1

120oC

1hr40min

15

Microwave
irradiation
Microwave
irradiation
Microwave
irradiation
Microwave
irradiation
Microwave
irradiation
Microwave
irradiation

No

Yes

Fluorescence experiments
Using the intrinsic Tryptophan (Trp) in Cdc42(WT) and Cdc42(T35A), fluorescence
spectroscopy was performed. This was done via a protein denaturation experiment by performing
an increasing concentration gradient of Guanidine Hydrochloride (GnHCl) in the presence and
absence of 10 µM AZA197. The data was collected using a Hitachi f2500 fluorometer with an
excitation wavelength of 280 nm and an emission collection range of 300-400 nm.
Using the data collected the fraction of denaturation (Fd), equilibrium constant (Keq),
denaturation concentration (Cm), and Gibbs free energy (∆G) were determined. Fd is obtain by
equation 1.
𝐹𝐹−𝐹𝐹𝑛𝑛

𝐹𝐹𝑑𝑑 = 𝐹𝐹

𝐷𝐷 −𝐹𝐹𝑛𝑛

(Eq.1)

F corresponds to the relative fluorescence reading at any given point. Fn is the
fluorescence reading of the native protein before any denaturant is added. FD, corresponds to the
fluorescence reading of the completely denatured protein. The equilibrium constant is obtained
by equation 2.
𝐹𝐹

𝐾𝐾𝑒𝑒𝑒𝑒 = 1−𝐹𝐹𝑑𝑑

𝑑𝑑

(Eq.2)

The use of the equilibrium constant can be used to solve for the Gibbs free energy of
protein unfolding, equation 3.
∆𝐺𝐺𝑑𝑑 = −𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅(𝐾𝐾𝑒𝑒𝑒𝑒 )

(Eq.3)

The ideal gas constant (R) used was 8.314 J mol-1 K-1, and 298 K was the temperature (T)
used for the determination of the Gibbs free energy. The use of equation 3 allows us to use
equation (4) to find the Gibbs free energy of the protein unfolding in the absence of no protein
denaturant (∆Gd,H2O ).

∆𝐺𝐺𝑑𝑑 = ∆𝐺𝐺𝑑𝑑,𝐻𝐻2𝑂𝑂 − 𝑚𝑚[𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺]
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(Eq.4)

To solve for ΔGdH2O (y-intercept), a derivative of the slope-intercept equation is used. The
slope is represented by m[GnHCl] and changes with respect to increasing [GnHCl]. All
denaturation experiments were performed in triplicates in the presence and absence of 10 µM
AZA197 and 100 mL of 1 mg/mL of protein.
Table 3.1 and Table 3.2 demonstrate the values obtained from the fluorescence
experiments in the presence and absence of the small molecule AZA197 with increasing
concentrations of GnHCl. The fluorescence intensity was normalized by using Eq. 1 to find the
Fd for each point. Since each sample was triplicated the Fd represented is the average of the
samples and the standard error was obtained in order to used them for error values. The Fd was
then used to calculate the equilibrium constant (Keq) followed by the determination of Gibbs free
energy (ΔGd). Figure 3.9 and Figure 3.10 are a graphical representation of the fraction of
denaturation from Tables 3.3 and Table 3.4, respectively with increasing concentration of GnHCl
in the presence and absence of AZA197.

Table 3.3 Demonstrates the data used to graph the fractions of denaturation with
increasing concentration of GnHCl of Cdc42(WT) in the absence and presence of 10 µM
AZA197, respectively.
Cdc42(WT) + AZA197 Standard
[GnHCl] Cdc42(WT) Fd
Standard Error
Fd
Error
0
0
0
0
0
1
0.3255
0.05977
0.33572
0.04047
2
2.5
3
3.5
4.5
5
5.4

0.75437
0.65448
0.66419
0.69207
0.7862
0.84542
1

0.17948
0.09153
0.05121
0.03227
0.05696
0.0241
0
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0.556
0.61069
0.59782
0.62767
0.77871
0.93273
1

0.11859
0.11734
0.0934
0.0496
0.08101
0.03363
0

Figure 3.9 The fraction of denaturation in the absence (red) and presence (black) of 10
µM AZA197 with increasing concentrations of denaturant (GnHCl) for Cdc42(WT). The
numerical values used can be found on Table 3.1. The data was analyzed using Origin software.
Table 3.4. Demonstrates the data used to graph the fraction of denaturation with
increasing concentration of GnHCl of Cdc42(T35A) in the absence and presence of 10 µM
AZA197, respectively.
Standard
Cdc42(T35A)+
Standard
[GnHCl] Cdc(T35A) Fd
Error
AZA197 Fd
Error
0
0
0
0
0
1
0.71974
0.01656
0.64858
0.03433
1.5
0.80246
0.00345
0.73959
0.02023
2
0.8325
0.01494
0.74068
0.05578
2.5
0.90647
0.01454
0.78292
0.03707
3
0.91419
0.01798
0.81606
0.0279
3.5
0.94599
0.0187
0.83875
0.04071
4.5
0.97234
0.01332
0.92051
0.02639
5
1
0
0.97471
0.00943
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Figure 3.10. The fraction of denaturation in the absence (red) and presence (black) of 10
µM AZA197 with increasing concentrations of denaturant (GnHCl) for Cdc42(T35A). The
numerical values used can be found on Table 3.2. The data was analyzed using Origin software.
The Cm is the concentration of the denaturant were the folded and unfolded proteins are
in equilibrium. The Fd of 0.5 was used to determine the Cm values for each data set. As seen in
Table 3.5 the Cm values of Cdc42(WT) and Cdc42(T35A) implies that there is no significant
change in the presence and absence of AZA197. This suggest that AZA197 does not have an
effect on the overall stability of the proteins.
Table 3.5 Cm values in the presence and absence of AZA197 for Cdc42(WT) and Cdc42(T35A).
Cm
Cdc42(WT)
1.49
Cdc42(WT) + AZA197
1.37
Cdc42(T35A)
0.69
Cdc42(T35A) + AZA197
0.75
Tables 3.6 and Table 3.7 Exhibit the Gibbs free energy in respects to increasing
concentration of GnHCl in the presence and absence of 10 µM AZA197 for Cdc42(WT) and
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Cdc42(T35A), respectively. Figure 3.11 and figure 3.12 are a graphical representation of the
Gibs free energy of the Tables 3.6 and 3.7, respectively.
Table 3.6. The Gibbs free energy of protein unfolding in the absence of the denaturant
for Cdc42(WT)
[GnHCl]
ΔGd Cdc42(WT)
ΔGd Cdc42(WT) + AZA197
1
1805.1416
1692.172
1.5
-335.7254
-1116.369
2.5
-1582.294
-982.8852
3
-1689.776
-1294.915
3.5
-2006.36
-3119.765
4.5
-3226.281
-6520.107

Figure 3.11. The denatured Gibbs free energy (ΔGd) of Cdc42(WT)in the presence and
absence of AZA197 in respect to increasing concentrations of GnHCl. The data points were
derived from the Fd. The data was analyzed using Origin software.
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Table 3.7. The Gibbs free energy of the protein unfolding in the absence of the denaturant. For
Cdc42(T35A).
[GnHCl]
ΔGd Cdc(T35A)
ΔGd Cdc(T35A)+ AZA197
1
-969.7889
-1518.399
2
-2336.356
-2600.4174
2.5
-3973.171
-3178.3404
3
-5626.093
-3691.4551
3.5
-5860.508
-4085.7334
4.5
-7092.292
-6068.7436

Figure 3.12. The denatured Gibbs free energy (ΔGd) of Cdc42(T35A)in the presence and
absence of AZA197 in respect to increasing concentrations of GnHCl. The data points were
derived from the Fd. The data was analyzed using Origin software.
For Cdc42 (WT) Keq and ∆Gd have a significant difference suggesting that in the
presence of the small molecule seems to have an influence. As its signified in Table 3.8, in the
presence of the small molecule there is an increase in ∆Gd,H2O and the slope, meaning that in the
presence of AZA197 it unfolds at a slower rate. For Cdc42(T35A), the small molecule seems to
have an opposite influence on unfolding relative to the wild type. There is a significant change in
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the Fd, Keq, and ∆Gd. Suggesting that AZA197 destabilizes Cdc42(T35A), not interacting in the
same manner as compared to the wild type.
Table 3.8. The Gibbs free energy of unfolding in the absence of no protein denaturant
and its corresponding slope determined by Eq.4
DGd,H2O (kJ/mol)
m[GnHCl] (kJ/L)
Cdc42(WT)
2.587
-1.367
Cdc42(WT)+AZA197
4.057
-2.162
Cdc42(T35A)
0.825
-1.867
Cdc42(T35A) +AZA197
-0.09134
-1.248
Chapter IV-Conclusion
The biophysical characterizations of the small molecule, AZA197, and Cdc42 are
important for its potential use as an anticancer drug therapy. It has been demonstrated that Cdc42
is tissue specific, and it can be either be upregulated or downregulated in cancer. In those
malignancies that have been associated with Cdc42 upregulation, small molecules have been
used to inhibit the interaction with downstream effector proteins, reducing its overactivity.
The discovery of the small molecule AZA197 demonstrates its potential use as an
anticancer drug therapy as it has high selectivity to Cdc42 among other Rho related proteins.
Nonetheless, to understand Cdc42 and AZA197 interactions at a molecular level, more
biophysical characterizations need to be performed. AZA197 was synthesized and its interactions
with Cdc42(WT) and Cdc42(T35A) were studied with increasing concentrations of GnHCl.
This biophysical characterization demonstrated that Cdc42(WT) is more stable in the
presence of the small molecule under increasing concentrations of the denaturant. The Gibbs free
energy of the protein unfolding was determined via fluorescence experiments, and an increase
was demonstrated in the presence of AZA197.
This suggested that AZA197 helps stabilize Cdc42(WT). In contrast, the fluorescence
denaturation experiments with Cdc42(T35A) in the presence and absence of the small molecule
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has a negative effect making it more destabilized in comparison to Cdc42(WT). This data
suggested that Cdc42(T35A) has no positive interaction with AZA197. Cdc42(T35A) is in the
Switch I region that is highly conserved in Cdc42(WT), where its flexibility allows for its
interactions with downstream effector proteins once the protein is in the active state. The data
suggest that AZA197 binds to the Switch I region which could lead to a potential inhibition to its
overall activity.
However, to better understand the molecular interactions of Cdc42(WT) and
Cdc42(T35A) with AZA197 more experiments should be performed. Future experiments that
could give a better understanding of its interactions would be a time-dependent fluorescence
denaturation experiment, Isothermal Calorimetry (ITC), NMR, and GTP hydrolysis. These
would allow for the understanding of the interactions between Cdc42 and AZA197 at a
molecular level to determine AZA197’s potential as an anticancer drug therapy.
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